Table 2.

First events contributing to progression-free survival

	FEC arm (N=361)*	T-ET arm (N=314)*
	N (%)	N (%)
Progression while on neoadjuvant chemotherapy	30 (8.3)	29 (9.2)
Distant recurrence	279 (77.3)	243 (77.4)
Invasive loco-regional recurrence	27 (7.5)	21 (6.7)
Invasive contralateral cancer	12 (3.3)	12 (3.8)
Death without prior report of progression	13 (3.6)	9 (2.9)
Progression	2	0
Treatment toxicity‡	1	1
Cancer (non-breast)	5	2
Cardiovascular	1	3
Other	0	2
Unknown	4	1

Abbreviations and legend:

FEC: fluorouracil, epirubicin, cyclophosphamide; T-ET: docetaxel followed by epirubicin and docetaxel;

^*Respectively 361 and 314 had a progression-free survival qualifying event

^‡Deaths occuring during chemotherapy or within 30 days of chemotherapy completion and without disease relapse.